Artelo Biosciences Soars 30.5% on Promising Depression Drug Data

Artelo Biosciences, Inc. (ARTL) has seen a remarkable surge of 30.5% in pre-market trading on July 9, 2025, driven by the release of positive preclinical data for its drug candidate, ART12.11. The data demonstrated significant improvements in depression-related behaviors in animal models and reversed cognitive deficits associated with chronic stress, showing efficacy comparable to Pfizer's antidepressant Zoloft.

This positive data release has sparked investor interest, leading to a substantial increase in the company's stock price. The preclinical results suggest that ART12.11 has the potential to be a highly effective treatment for stress-induced depression, which could position Artelo Biosciences as a key player in the mental health treatment market.

The company's focus on developing innovative therapies for mental health conditions has been a driving force behind its recent success. With the promising preclinical data for ART12.11, Artelo Biosciences is poised to continue its growth trajectory and potentially attract further investment and partnerships in the biopharmaceutical industry.